Description

BSE received clarifications from 60 listed companies regarding significant price/volume movement observed in their scrips. Replies are awaited from a few additional companies.

Summary

BSE (Notice No. 20260409-38) observed significant price and volume movement in a large number of listed equity scrips and, in order to ensure trading members and investors have the latest relevant information, wrote to the concerned companies seeking clarifications. Replies have been received from 60 companies and are attached as ten separate reply documents. A small number of companies are still awaited.

Key Points

  • BSE identified unusual price/volume activity across 60+ scrips under its market surveillance function.
  • Clarifications have been received from 60 companies; replies are attached as Replies1 through Replies10.
  • At least three companies — Tejnaksh Healthcare Ltd (539428), ZR2 Bioenergy Ltd (506640), and Abram Food Ltd — had not yet responded as of notice date.
  • The notice is issued by the DOSS (Department of Surveillance & Supervision) under the Equity segment.
  • No trading halt or suspension has been announced; the action is disclosure/clarification-oriented.

Regulatory Changes

No new regulatory changes introduced. This is a standard surveillance-driven disclosure exercise under existing BSE guidelines requiring listed companies to explain abnormal market activity in their securities.

Compliance Requirements

  • Companies that have not yet submitted replies (Tejnaksh Healthcare Ltd, ZR2 Bioenergy Ltd, Abram Food Ltd, and others not listed due to truncation) are required to respond to BSE’s query promptly.
  • All 60 companies that have responded have fulfilled their immediate disclosure obligation; investors and trading members should review the attached reply documents for company-specific disclosures.

Important Dates

  • Notice Date: 09 April 2026
  • Replies received: As of 09 April 2026 from 60 companies
  • Pending replies: Awaited from at least 3 companies as of notice date

Impact Assessment

The circular affects a broad cross-section of BSE-listed small and mid-cap companies across diverse sectors including chemicals, infrastructure, IT, pharma, textiles, and real estate. Since clarifications have been filed by the majority of queried companies, immediate market disruption is limited. However, investors in the listed scrips — particularly those still awaiting replies — should exercise caution until full disclosures are available. The surveillance action signals heightened regulatory scrutiny on these counters, which may temporarily affect sentiment.

Impact Justification

Routine BSE surveillance action involving 60+ companies with abnormal price/volume activity; affects a broad set of scrips but is informational in nature with clarifications already filed.